Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NeuroPace ( (NPCE) ) has shared an announcement.
On June 6, 2025, NeuroPace, Inc. conducted its Annual Meeting of Stockholders virtually, where key proposals were voted on. Stockholders elected Class I director nominees Joel Becker and Frank Fischer to serve until the 2028 Annual Meeting. Additionally, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.
The most recent analyst rating on (NPCE) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on NeuroPace stock, see the NPCE Stock Forecast page.
Spark’s Take on NPCE Stock
According to Spark, TipRanks’ AI Analyst, NPCE is a Neutral.
NeuroPace’s overall stock score is primarily impacted by its financial performance challenges, including high leverage and cash flow issues. However, strong earnings call guidance, positive corporate events, and revenue growth potential provide a balanced outlook.
To see Spark’s full report on NPCE stock, click here.
More about NeuroPace
NeuroPace, Inc. operates in the medical technology industry, focusing on developing and providing innovative neurostimulation devices for the treatment of neurological disorders.
Average Trading Volume: 286,918
Technical Sentiment Signal: Buy
Current Market Cap: $424.4M
Learn more about NPCE stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue